| | Business Summary | | Advanced
Tissue
Sciences,
Inc.
is
engaged
in
the
field
of
tissue
engineering,
using
its
patented
technology
to
develop
human-based
tissue
products
for
a
variety
of
therapeutic
applications.
The
Company
uses
principles
of
cell
biology,
bioengineering,
biochemistry,
polymer
science
and
transplant
science
in
order
to
culture
living
human
cells,
either
within
(in
vivo)
or
outside
(ex
vivo)
the
human
body,
in
a
way
that
allows
the
cells
to
develop
and
assemble
into
a
functioning
three-dimensional
tissue.
With
this
human-based
tissue
development
technology,
the
Company
has
successfully
replicated
a
number
of
human
tissues
that
are
being
developed
for
the
purpose
of
replacing
or
repairing
diseased,
damaged
or
aging
tissue
and
organs.
The
Company
is
targeting
four
distinct
therapeutic
areas:
wound
care,
aesthetics
and
reconstruction,
orthopedics
and
cardiovascular
care. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | ATIS
is
a
tissue
engineering
company,
engaged
in
the
development
of
human-based
tissue
products
for
therapeutic
applications.
ATIS
focuses
on
wound
care,
orthopedics,
aesthetic,
reconstructive
and
cardiovascular
products.
For
the
six
months
ended
6/30/01,
revenues
fell
24%
to
$10.4
million.
Net
loss
applicable
to
Common
rose
12%
to
$17.6
million.
Results
reflect
a
decrease
in
Dermagraft
JV
milestone
sales
and
lower
operating
margins. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Arthur Benvenuto, 57
Chairman
of Directors and CEO | $548K | Gail Naughton, 45
Pres,
Director | 411K | Nikhil Mehta, 44
Sr.
VP, CFO | -- | Joseph Kletzel, II, 51
Exec.
VP, COO | 336K | Mark Gergen, 38
VP,
Gen. Counsel, Sec. | -- | | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/a/atis.gif)